Retina Today - Latest News http://retinatoday.com/ The latest news stories from Retina Today. en-us Mon, 20 Nov 2017 01:03:49 GMT Mon, 20 Nov 2017 01:03:49 GMT BMCToday RETROSPECTIVE STUDY: L-DOPA WAS PROTECTIVE AGAINST WET AMD http://retinatoday.com/2016/02/01/retrospective-study-l-dopa-was-protective-against-wet-amd Exogenous L-DOPA appeared to protect against the development of wet age-related macular degeneration (AMD) in multiple cohorts of patients, according to a retrospective study published in the American Journal of Medicine.1 Researchers analyzed medical records to compare the incidence of AMD in patients taking L-DOPA and... Mon, 1 Feb 2016 04:00:00 GMT http://retinatoday.com/2016/02/01/retrospective-study-l-dopa-was-protective-against-wet-amd Delayed Rod-Mediated Dark Adaptation Linked With Doubled Risk of AMD http://retinatoday.com/2016/02/01/delayed-rod-mediated-dark-adaptation-linked-with-doubled-risk-of-amd Patients with delayed rod-mediated dark adaptation were nearly twice as likely as patients with normal dark adaptation to develop AMD by 3 years after initial testing, according to a study published in Ophthalmology.1 Baseline and follow-up visits were completed by 325 patients with stage 1 normal vision as defined by t... Mon, 1 Feb 2016 04:00:00 GMT http://retinatoday.com/2016/02/01/delayed-rod-mediated-dark-adaptation-linked-with-doubled-risk-of-amd Dexamethasone Implant, Given at 6-Month Intervals, Sustained Improvement for 3 Years http://retinatoday.com/2016/02/01/dexamethasone-implant-given-at-6-month-intervals-sustained-improvement-for-3-years The dexamethasone intravitreal implant (Ozurdex, Allergan) produced sustained retinal structural improvement in patients with diabetic macular edema (DME) when administered in doses of 0.7 mg or 0.35 mg at 6-month intervals, according to a study published in the British Journal of Ophthalmology.1 Researchers analyzed da... Mon, 1 Feb 2016 04:00:00 GMT http://retinatoday.com/2016/02/01/dexamethasone-implant-given-at-6-month-intervals-sustained-improvement-for-3-years Fluocinolone Acetonide Implant Met Primary Phase 3 Endpoint for Noninfectious Posterior Uveitis http://retinatoday.com/2016/02/01/fluocinolone-acetonide-implant-met-primary-phase-3-endpoint-for-noninfectious-posterior-uveitis Treatment of noninfectious posterior uveitis with a fluocinolone acetonide implant (Medidur, pSivida) prevented disease recurrence at a higher rate than sham injection, thus meeting the primary endpoint in a phase 3 clinical trial, according to a company press release. Researchers in a phase 3 multicenter, double-masked... Mon, 1 Feb 2016 04:00:00 GMT http://retinatoday.com/2016/02/01/fluocinolone-acetonide-implant-met-primary-phase-3-endpoint-for-noninfectious-posterior-uveitis Suprachoroidal Space TA Formulation Advances in Clinical Trials http://retinatoday.com/2016/02/01/suprachoroidal-space-ta-formulation-advances-in-clinical-trials A proprietary form of triamcinolone acetonide for injection into the suprachoroidal space (CLA-TA; Clearside Biomedical) for the treatment of noninfectious uveitis met primary and secondary endpoints in the Dogwood clinical trial, according to a company press release of top-line data. Clearside also announced updates on the... Mon, 1 Feb 2016 04:00:00 GMT http://retinatoday.com/2016/02/01/suprachoroidal-space-ta-formulation-advances-in-clinical-trials Phase 2 Gene Therapy Trial Begins Enrollment http://retinatoday.com/2016/02/01/phase-2-gene-therapy-trial-begins-enrollment A phase 2 clinical trial assessing the safety and efficacy of a gene therapy approach to treatment of choroideremia has begun enrolling patients at the University of Miami Miller School of Medicine. Researchers will deliver a wild-type copy of the Rab-escort protein 1 (REP1) gene using an adeno-associated virus (AAV2-RE... Mon, 1 Feb 2016 04:00:00 GMT http://retinatoday.com/2016/02/01/phase-2-gene-therapy-trial-begins-enrollment Phase 2b DME Trial Completes Enrollment http://retinatoday.com/2016/02/01/phase-2b-dme-trial-completes-enrollment A phase 2b trial assessing the safety and efficacy of ALG-1001 (Luminate, Allegro) as DME therapy has completed enrollment. The company expects to report top-line data by the third quarter of 2016. DEL MAR is a double-masked, placebo-controlled, multicenter 6-month phase 2b trial evaluating the safety and efficacy of in... Mon, 1 Feb 2016 04:00:00 GMT http://retinatoday.com/2016/02/01/phase-2b-dme-trial-completes-enrollment Widefield Imaging Device Cleared for Use in Infants http://retinatoday.com/2016/02/01/widefield-imaging-device-cleared-for-use-in-infants The US Food and Drug Administration has granted clearance to the PanoCam LT Widefield Imaging System (Visunex) for the imaging of all newborn infants. The device is a compact, wireless imaging system designed to detect a number of external, anterior, and posterior segment vision disorders.... Mon, 1 Feb 2016 04:00:00 GMT http://retinatoday.com/2016/02/01/widefield-imaging-device-cleared-for-use-in-infants Preliminary Data: Anti-VEGF Eyedrop for Wet AMD Treatment Showed No Safety Concerns http://retinatoday.com/2016/02/01/preliminary-data-anti-vegf-eyedrop-for-wet-amd-treatment-showed-no-safety-concerns No treatment-related adverse events have been reported in a phase 1/2 study evaluating the anti-VEGF eyedrop PAN-90806 (PanOptica) for the treatment of neovascular AMD. Anti-VEGF biological activity was observed in all monotherapy dose arms of the study. A full data set will be available in 2016. According to the compan... Mon, 1 Feb 2016 04:00:00 GMT http://retinatoday.com/2016/02/01/preliminary-data-anti-vegf-eyedrop-for-wet-amd-treatment-showed-no-safety-concerns First Retina World Congress Will Convene in Spring 2017 http://retinatoday.com/2016/02/01/first-retina-world-congress-will-convene-in-spring-2017 The inaugural Retina World Congress will be held February 23 to 26, 2017, in Fort Lauderdale, Fla., the meeting’s organizers announced. The proceedings of the meeting will be published in The International Journal of Retina and Vitreous. Rishi P. Singh, MD, will serve as president of the Retina World Congress. n... Mon, 1 Feb 2016 04:00:00 GMT http://retinatoday.com/2016/02/01/first-retina-world-congress-will-convene-in-spring-2017 Cleveland Clinic Chose Top 10 Medical Innovations for 2015 http://retinatoday.com/2014/12/10/cleveland-clinic-chose-top-10-medical-innovations-for-2015 Stem Cells Showed Promise for Stroke Recovery Infusing stem cells into the brain may help boost recovery after a stroke, according to a pilot study published in Stem Cell Translational Medicine.1 The therapy used CD34+ cells, a set of stem cells in the bone marrow that give rise to blood cells and blood vessel lining ce... Wed, 10 Dec 2014 04:00:00 GMT http://retinatoday.com/2014/12/10/cleveland-clinic-chose-top-10-medical-innovations-for-2015 Cleveland Clinic Chose Top 10 Medical Innovations for 2015 http://retinatoday.com/2014/12/10/cleveland-clinic-chose-top-10-medical-innovations-for-2015 Stem Cells Showed Promise for Stroke Recovery Infusing stem cells into the brain may help boost recovery after a stroke, according to a pilot study published in Stem Cell Translational Medicine.1 The therapy used CD34+ cells, a set of stem cells in the bone marrow that give rise to blood cells and blood vessel lining ce... Wed, 10 Dec 2014 04:00:00 GMT http://retinatoday.com/2014/12/10/cleveland-clinic-chose-top-10-medical-innovations-for-2015 News http://retinatoday.com/2014/12/10/news Retina specialists performing vitrectomy procedures billed through Medicare will receive reduced reimbursement from the publicly funded health care program starting on January 1, 2015. The Centers for Medicare and Medicaid Services (CMS) announced its intention to reduce vitrectomy reimbursement in July 2014. The p... Wed, 10 Dec 2014 04:00:00 GMT http://retinatoday.com/2014/12/10/news Q&A with Actavis and Allergan CEOs Following Blockbuster Deal http://retinatoday.com/2014/12/10/qa-with-actavis-and-allergan-ceos-following-blockbuster-deal On November 17, in what would be the year’s largest acquisition in any industry, Actavis announced plans to acquire Allergan for $66 billion in cash and stock. Actavis, a specialty and generic drug maker, said it would pay $219 per Allergan share, made of about 60% in cash and the rest in Actavis stock. Although ... Wed, 10 Dec 2014 04:00:00 GMT http://retinatoday.com/2014/12/10/qa-with-actavis-and-allergan-ceos-following-blockbuster-deal VIBRANT, NEWTON Trials Showed Aflibercept Effective in Treating RVO http://retinatoday.com/2014/12/10/vibrant-newton-trials-showed-aflibercept-effective-in-treating-rvo Monthly intravitreal aflibercept (Eylea, Regeneron) injections provided significantly greater visual benefit and reduction in central retinal thickness (CRT) at 24 weeks compared with grid laser photocoagulation in eyes with branch retinal vein occlusion (BRVO) in the VIBRANT trial, Robert E. Leonard II, MD, reported.1... Wed, 10 Dec 2014 04:00:00 GMT http://retinatoday.com/2014/12/10/vibrant-newton-trials-showed-aflibercept-effective-in-treating-rvo Fluocinolone Acetonide Intravitreal Implant Approved by FDA for Treatment of DME http://retinatoday.com/2014/10/15/fluocinolone-acetonide-intravitreal-implant-approved-by-fda-for-treatment-of-dme The US Food and Drug Administration (FDA) approved the fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien, Alimera Sciences) for treatment of diabetic macular edema (DME), according to a press release.1 The drug is approved for treatment of DME in patients who have been previously treated with a course of cor... Wed, 15 Oct 2014 04:00:00 GMT http://retinatoday.com/2014/10/15/fluocinolone-acetonide-intravitreal-implant-approved-by-fda-for-treatment-of-dme FDA Approved Changed Label for Dexamethasone Implant, Drug Approved for DME in Europe http://retinatoday.com/2014/10/15/fda-approved-changed-label-for-dexamethasone-implant-drug-approved-for-dme-in-europe The FDA approved a revised indication for the dexamethasone intravitreal implant (Ozurdex, Allergan) for the treatment of DME, according to a press release.1 The revised indication allows for the drug’s use in the general DME patient population. The FDA had previously approved the drug in June 2014 for the treatment ... Wed, 15 Oct 2014 04:00:00 GMT http://retinatoday.com/2014/10/15/fda-approved-changed-label-for-dexamethasone-implant-drug-approved-for-dme-in-europe Study Found Variations in Protein Concentration in Compounded Bevacizumab http://retinatoday.com/2014/10/15/study-found-variations-in-protein-concentration-in-compounded-bevacizumab Significant variations in protein concentration were detected in bevacizumab (Avastin, Genentech) acquired from compounding pharmacies compared with bevacizumab acquired from the drug manufacturer, according to a study published in JAMA Ophthalmology.1 In a prospective study, researchers at Weill Cornell Medical Col... Wed, 15 Oct 2014 04:00:00 GMT http://retinatoday.com/2014/10/15/study-found-variations-in-protein-concentration-in-compounded-bevacizumab Supplement Increased Risk for Macular Degeneration in Particular Genotype Group, Study Found http://retinatoday.com/2014/10/15/supplement-increased-risk-for-macular-degeneration-in-particular-genotype-group-study-found Patients with a particular genotype assigned to zinc or a zinc-containing supplement intended to slow the progression of age-related macular degeneration (AMD) were found to have an increased risk for developing the disease compared with patients of the same genotype who took a placebo, according to a study published i... Wed, 15 Oct 2014 04:00:00 GMT http://retinatoday.com/2014/10/15/supplement-increased-risk-for-macular-degeneration-in-particular-genotype-group-study-found Retina Specialists Differ in Patient Advice Versus Self-Advice http://retinatoday.com/2014/10/15/retina-specialists-differ-in-patient-advice-versus-self-advice Retina specialists were more likely to prescribe bevacizumab for treatment of exudative AMD to patients, but were equally likely to prescribe bevacizumab, ranibizumab (Lucentis, Genentech), or aflibercept (Eylea, Regeneron) for themselves if they were to have the disease, according to survey results published in Retina... Wed, 15 Oct 2014 04:00:00 GMT http://retinatoday.com/2014/10/15/retina-specialists-differ-in-patient-advice-versus-self-advice